Race to control silent liver disease hits pause
NCT ID NCT04104321
Summary
This study is testing whether a drug called Aramchol can reduce liver scarring and inflammation in people with NASH, a serious fatty liver disease. The trial involves about 150 adults with confirmed NASH and some liver scarring. It compares Aramchol against a placebo to see if it improves liver health and prevents disease progression, but the study is currently suspended.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Texas Clinical Research Institute, LLC
Arlington, Texas, 76012, United States
-
The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health System
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.